Analysts Offer Insights on Healthcare Companies: Mesoblast Ltd (NASDAQ: MESO) and Evofem Biosciences Inc (NASDAQ: EVFM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast Ltd (MESOResearch Report) and Evofem Biosciences Inc (EVFMResearch Report) with bullish sentiments.

Mesoblast Ltd (MESO)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Mesoblast Ltd today and set a price target of $6.50. The company’s shares closed last Monday at $4.95.

Ramakanth observed:

“We derive a 12-month price target of $6.50 per share based on an NPV analysis of projected product revenues through FY2030. We assume a 12.2% discount rate, formulated by our calculation of Mesoblast’s weighted average cost of capital, and 3% terminal growth rate. We derive an NPV of $1.1B and subtract net debt of $9.2M to arrive at a 12-month price target of $6.74, which we round to $6.50. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property.”

According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.3% and a 28.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast Ltd with a $9.33 average price target.

See today’s analyst top recommended stocks >>

Evofem Biosciences Inc (EVFM)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Evofem Biosciences Inc today and set a price target of $9. The company’s shares closed last Monday at $5.02.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -13.2% and a 25.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

Evofem Biosciences Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.